Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill

Executive Summary

Innovator biologics may be in for added pricing pressure from biosimilars under Medicare Part B payment and billing code requirements in the House health reform bill unveiled Oct. 29

You may also be interested in...



Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score

The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry

Follow-On Biologics' Other Pathway: Mechanisms To Resolve Patent Disputes Vary In Legislation

The debate over follow-on biologics legislation has largely focused on the length of data exclusivity that should be awarded to innovators. But provisions for resolving patent disputes between innovators and follow-on applicants are also a source of contention

Follow-On Biologics' Other Pathway: Mechanisms To Resolve Patent Disputes Vary In Legislation

The debate over follow-on biologics legislation has largely focused on the length of data exclusivity that should be awarded to innovators. But provisions for resolving patent disputes between innovators and follow-on applicants are also a source of contention

Related Content

Topics

UsernamePublicRestriction

Register

PS051633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel